154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

Mara Persano; M. Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; F. Finkelmeier; Hyoseob Lim; José Presa; Gianluca Masi; Francesca Bergamo; Massimo Iavarone; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Fabio Piscaglia; S. Cascinu; M. Scartozzi

doi:10.1016/j.annonc.2023.10.289

Article2023

88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Hye Yeon Lim, José Presa, Gianluca Masi, Francesca Bergamo, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, F. Piscaglia, Stefano Cascinu, M. Scartozzi

Article2024

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Federico Rossari, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone,

Article2025

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Sohyun Hwang, Dong Jun Shin, Beodeul Kang, Haeyoun Kang, Sung Hwan Lee, Jung Sun Kim, Je‐Gun Joung, Suyog Jain, Steven R. Olsen, Lars Becker, Richard S. Finn, Josep M. Llovet, Gwangil Kim, Chan Kim, Hong Jae Chon

Article2024

Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Ciro Celsa, Bernardo Stefanini, Jaekyung Cheon, Celina Ang, Thomas U. Marron, Anwaar Saeed, Brooke Wietharn, Tiziana Pressiani, Matthias Pinter, Bernhard Scheiner, Yi‐Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, F. Piscaglia, Rong Lin, Chih-Yun Lin, Andrea Dalbeni, Caterina Vivaldi, Gianluca Masi, Robert Thimme,

Article2023

173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)

Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, F. Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, F. Bergamo, M.A. Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, F. Piscaglia, Stefano Cascinu, M. Scartozzi, A. Casadei Gardini

154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

Discussion(0)

Related publications

88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)